	US 12,331,078 B2
	Stabilizing mutants of prefusion SARS-CoV-2 (COVID-19) spike protein and improved yeast surface display engineering platform for the same
Timothy Whitehead, Boulder, CO (US); Monica Kirby, Boulder, CO (US); Zachary Baumer, Boulder, CO (US); Matthew Bedewitz, Boulder, CO (US); Brian Petersen, Boulder, CO (US); and Paul J. Steiner, Boulder, CO (US)
Assigned to The Regents of the University of Colorado, a body corporate, Denver, CO (US)
Filed by The Regents of the University of Colorado, a body corporate, Denver, CO (US)
Filed on May 12, 2021, as Appl. No. 17/318,719.
Claims priority of provisional application 63/062,123, filed on Aug. 6, 2020.
Claims priority of provisional application 63/026,316, filed on May 18, 2020.
Prior Publication US 2021/0355170 A1, Nov. 18, 2021
Int. Cl. C07K 14/005 (2006.01); A61K 31/427 (2006.01); C12N 15/81 (2006.01); A61K 39/00 (2006.01)

CPC C07K 14/005 (2013.01) [C12N 15/81 (2013.01); A61K 39/00 (2013.01); C12N 2770/20022 (2013.01); C12N 2770/20034 (2013.01)]

13 Claims

1. An isolated spike protein, or a fragment thereof, from a SARS-CoV-2 coronavirus having one or more stabilizing mutations selected from: K41N, K41P, K41S, R44K, K113F, T114D, Q115I, or Q115H, wherein the position of the one or more mutations corresponds to the spike protein encoded by the amino acid sequence according to SEQ ID NO. 2.